Canopy Growth shares see a jump — What is fueling the stock rise

Traders Union
All News
Financial News
Canopy growth rises 4.41% today

Highlights

Canopy Growth finalized its acquisition of MTL Cannabis Corp, issuing 41.2 million shares and C$18.5 million in cash to consolidate market position.
The combined entity seeks to lead Canada's medical cannabis segment by revenue following recent debt restructuring, which extended maturities to 2031 and eased near-term financial pressures.
Shares remain under pressure, trading in an extended downtrend below key moving averages, with technical signals favoring continued downside and a projected range of $0.99 to $1.11 over the next week.

Strategic acquisitions and debt moves boost financial stability outlook

Canopy Growth has completed its acquisition of MTL Cannabis Corp, issuing approximately 41.2 million shares and C$18.5 million in cash to MTL Cannabis shareholders. With this transaction, the company consolidates two major Canadian cannabis producers, aiming to create the country's leading medical cannabis business by revenue. Canopy Growth recently concluded a debt restructuring, which extends maturities to 2031 and improves its short-term financial position.

Anton Kharitonov, expert at Traders Union, observes that Canopy Growth’s weak technical profile overshadows the recent price pop. The stock has failed to regain any of its major moving averages. He believes the addition of MTL Cannabis and the debt restructuring have yet to shift the overall negative sentiment. The oversold indicators reflect sustained bearish control, limiting any bullish conviction. "Despite a temporary uptick, the risk of further downside remains elevated unless $1.13 is reclaimed," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, sees the MTL Cannabis acquisition and extended debt maturities as game-changing catalysts for Canopy Growth. He believes the move to consolidate leadership in Canadian medical cannabis will soon be reflected in investor sentiment. Market participants may soon position for a strategic rebound as confidence improves. He notes that the bullish structure remains intact once resistance at $1.13 is cleared. "I expect further growth opportunities as the new business model gains traction and buyers return," Karapetjanc states.

Parshwa Turakhiya, analyst, highlights that CGC offers a defined trading range with clear support near $0.99 and immediate resistance at $1.11 to $1.13. Short-term traders may spot opportunities given oversold readings, but the prevailing D1 momentum favors sellers. Sentiment will likely react to price tests at these key levels in the coming sessions. "I’d watch for a bounce attempt above $1.13, but prudent setups depend on a decisive move out of the current band," Turakhiya suggests.

Oversold momentum persists despite brief price uptick

The nearest dynamic support and resistance levels are at the Ichimoku Kijun ($1.11) and the SMA-50 ($1.13), respectively. Momentum on the D1 timeframe remains weak, with the MACD and ADX showing selling pressure and neutral trend strength. Both the RSI and CCI situate CGC in oversold territory, while the Stoch RSI further confirms oversold conditions, but BBP points to sellers dominating current intraday momentum. Despite today’s gain, there is a divergence between the short-lived intraday bounce and the prevailing negative momentum from D1 indicators.

Canopy Growth remained under sustained selling pressure, with technical indicators and moving averages reflecting a prevailing bearish trend. Today’s snapback on acquisition news introduces short-term volatility, but with negative momentum still dominating, traders should monitor for a possible downside break below $0.99 as the primary risk.

Source of Data: CGC Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.